Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cypress Pharmaceutical Inc.

Division of Pernix Therapeutics Holdings Inc.
www.cypressrx.com

Latest From Cypress Pharmaceutical Inc.

Pernix Reinvention Comes Down To Execution

Pernix has a new management team and a budding portfolio of CNS drugs, gained via M&A. Now the company needs to prove it can grow brands that compete in highly genericized markets and drive sustainable growth.

BioPharmaceutical Business Strategies

Biopharma Dealmaking Quarterly Statistics, Q4 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, December 2012

Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Deals Of The Week: Teva/Xenon, Biogen Idec/Isis, Bristol-Myers Squibb/The Medicines Company

Amgen’s unexpected buyout of deCode Genetics means the founder’s expensive philosophy of focusing on pioneering science rather than quick-to-market products finally will pay off for the Icelandic firm’s venture capital backers.

BioPharmaceutical Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register